Literature DB >> 8188395

Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters.

F Keller1, C Hörstensmeyer, M Looby, K Borner, W Pommer, K Erdmann, M Giehl.   

Abstract

A dose reduction of vancomycin to 1000 mg once a week usually is recommended for haemodialysis patients. Our modified dosing schedule consists of a loading dose of 1000 mg and a maintenance dose of 500 mg administered 3 times a week after haemodialysis. Different vancomycin regimens were retrospectively evaluated by therapeutic drug monitoring and bayesian parameter estimates in 39 dialysis patients. The mean (+/- SD) trough level in 7 patients receiving only the conventional dosage regimen was significantly lower than in 17 patients strictly treated by the modified schedule (7 +/- 4 versus 17 +/- 8 mg/L; p = 0.001). The corresponding peaks were low in both groups and no different (23 +/- 10 versus 27 +/- 12 mg/L). The one week average vancomycin clearance was significantly lower in the conventional dosage group compared to the modified dosage group (6 +/- 3 versus 10 +/- 3 ml/min; p = 0.001). High-flux dialysers were not used in the conventional dosage group but for 30 percent of the procedures in the modified dosage group, where the vancomycin one week average elimination half-life was 66 hours (+/- 18) and the volume of distribution 50 litres (+/- 5). As compared to the bayesian programme, NONMEM calculated comparable pharmacokinetic parameters but could be applied only in 5 cases with a sufficient number of concentration measurements. Ototoxicity occurred in 1 patient, whereas vancomycin treatment was judged as ineffective against infection in 5 of the 39 patients. Their troughs were below 15 mg/L.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188395

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  1 in total

1.  Evaluation of Factors which Influence Mortality in Gram-positive Bacteremia in Hemodialysis Patients.

Authors:  Kerry Anne Rambaran; Saeed K Alzghari; Charles F Seifert
Journal:  Cureus       Date:  2018-07-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.